Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Published bySpencer Baker Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before."— Presentation transcript:

1 Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab
Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab A 71-year-old woman was diagnosed in 2014 with small-cell lung cancer. In 2016, she was treated with nivolumab and ipilimumab for systemic recurrence. Four days later, she developed severe disorientation and short-term memory deficits. Brain MRI shows bilateral contrast-enhancing lesions with associated T2 hyperintensity of the hippocampi (A and B). The images normalize after 6 months of treatment with natalizumab (C and D). Andreas F. Hottinger et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e439 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Download ppt "Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before."

Similar presentations

Figure 2 ERG amplitude reduction in the follow-up study

Figure 2 ERG amplitude reduction in the follow-up study
Figure 2 Medial occipital lobe (designated by visual cortical brain regions) hypometabolism in anti–NMDA receptor encephalitis Medial occipital lobe (designated.

Figure 2 Medial occipital lobe (designated by visual cortical brain regions) hypometabolism in anti–NMDA receptor encephalitis Medial occipital lobe (designated.
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Regional changes in FA values

Figure 1 Regional changes in FA values
Figure 1 Brain MRI findings in the present case

Figure 1 Brain MRI findings in the present case
Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.

Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.
Figure MRI of anti-MOG-IgG–associated myelitis

Figure MRI of anti-MOG-IgG–associated myelitis
Figure 2 Spinal cord lesions

Figure 2 Spinal cord lesions
Figure Neuroimaging and pathology

Figure Neuroimaging and pathology
Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.

Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.

Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.

Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.

Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.
Figure 1 ERG peak time delay at baseline

Figure 1 ERG peak time delay at baseline
Figure 1 Quantitative spinal cord MRI maps and segmentations

Figure 1 Quantitative spinal cord MRI maps and segmentations
Figure 3 Gene expression in CSF cell pellets

Figure 3 Gene expression in CSF cell pellets

Similar presentations

Ads by Google